Statement of Changes in Beneficial Ownership (4)
January 16 2020 - 5:14PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
FIER IAN |
2. Issuer Name and Ticker or Trading Symbol
MOMENTA PHARMACEUTICALS INC
[
MNTA
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Mfg and Program Officer |
(Last)
(First)
(Middle)
C/O MOMENTA PHARMACEUTICALS, INC., 301 BINNEY STREET |
3. Date of Earliest Transaction
(MM/DD/YYYY)
1/14/2020 |
(Street)
CAMBRIDGE, MA 02142
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 1/14/2020 | | M(1) | | 8466 | A | $12.58 | 9648 | D | |
Common Stock | 1/14/2020 | | M(1) | | 33010 | A | $13.02 | 42658 | D | |
Common Stock | 1/14/2020 | | M(1) | | 4031 | A | $15.44 | 46689 | D | |
Common Stock | 1/14/2020 | | M(1) | | 26521 | A | $17.96 | 73210 | D | |
Common Stock | 1/14/2020 | | M(1) | | 15675 | A | $18.85 | 88885 | D | |
Common Stock | 1/14/2020 | | S(1) | | 46227 | D | $25 | 42658 | D | |
Common Stock | 1/14/2020 | | S(1) | | 41476 | D | $22 | 1182 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (Right to Buy) | $12.58 | 1/14/2020 | | M (1) | | 7055 | | 2/19/2017 | 5/20/2025 | Common Stock | 7055 | $0 | 0 | D | |
Stock Option (Right to Buy) | $12.58 | 1/14/2020 | | M (1) | | 1411 | | 11/19/2015 | 2/19/2023 | Common Stock | 1411 | $0 | 0 | D | |
Stock Option (Right to Buy) | $13.02 | 1/14/2020 | | M (1) | | 6712 | | 2/18/2019 | 2/18/2025 | Common Stock | 6712 | $0 | 0 | D | |
Stock Option (Right to Buy) | $13.02 | 1/14/2020 | | M (1) | | 26298 | | 11/18/2018 | 2/18/2025 | Common Stock | 26298 | $0 | 0 | D | |
Stock Option (Right to Buy) | $15.44 | 1/14/2020 | | M (1) | | 3976 | | 2/14/2016 | 5/15/2025 | Common Stock | 3976 | $0 | 0 | D | |
Stock Option (Right to Buy) | $15.44 | 1/14/2020 | | M (1) | | 55 | | 11/14/2015 | 2/14/2022 | Common Stock | 55 | $0 | 0 | D | |
Stock Option (Right to Buy) | $17.96 | 1/14/2020 | | M (1) | | 7449 | | 2/18/2018 | 2/18/2024 | Common Stock | 7449 | $0 | 0 | D | |
Stock Option (Right to Buy) | $17.96 | 1/14/2020 | | M (1) | | 19072 | | 11/18/2017 | 2/18/2024 | Common Stock | 19072 | $0 | 0 | D | |
Stock Option (Right to Buy) | $18.85 | 1/14/2020 | | M (1) | | 8312 | | 11/7/2019 | 2/7/2027 | Common Stock | 8312 | $0 | 6730 | D | |
Stock Option (Right to Buy) | $18.85 | 1/14/2020 | | M (1) | | 7363 | | 11/7/2019 | 2/7/2027 | Common Stock | 7363 | $0 | 395 | D | |
Explanation of Responses: |
(1) | This transaction was effected pursuant to a Rule 10b5-1 trading plan. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
FIER IAN C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE, MA 02142 |
|
| Chief Mfg and Program Officer |
|
Signatures
|
/s/ R. Mark Chamberlin as attorney in fact | | 1/16/2020 |
**Signature of Reporting Person | Date |
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Apr 2023 to Apr 2024